EGFR and non-small cell lung carcinoma: Similarly, a recent phase I dose escalation study (NCT02496663) evaluating necitumumab, a mAb that binds the extracellular domain of EGFR preventing receptor-ligand binding activation and inducing receptor internalisation [89], and osimertinib in patients with advanced NSCLC and resistant to prior EGFR TKI therapy has shown responses in 2/4 patients carrying Ex20ins, with a median PFS of 5.3 months [90].